Physician profile
Gary R Johnson
NPI 1114013513
$5,765.62
in general payments reported to CMS, 2019-2025
36 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $938 · 2021: $990 · 2022: $694 · 2023: $470 · 2024: $634 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.41 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $1,008.09 | 2024-2025 | Korlym |
| Novo Nordisk INC | $923.25 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $584.09 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $571.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $497.83 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $375.33 | 2019-2025 | |
| Amgen INC. | $205.62 | 2021-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $143.18 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.66 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.45 | 2019-2022 | |
| Abbvie INC. | $125.63 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.05 | 2022 | |
| Collegium Pharmaceutical, INC. | $109.69 | 2019-2025 | Belbuca |
| Idorsia Pharmaceuticals US INC | $106.78 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $82.02 | 2020-2025 | Mounjaro |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.